A Phase II Trial of Bortezomib (NSC 681239) + Lenalidomide (Revlimid, CC-5013) (NSC 703813) for Relapsed/Refractory Mantle Cell Lymphoma.

Trial Profile

A Phase II Trial of Bortezomib (NSC 681239) + Lenalidomide (Revlimid, CC-5013) (NSC 703813) for Relapsed/Refractory Mantle Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Feb 2013 Planned end date changed from 1 Jan 2100 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Planned end date changed from 1 Jun 2011 to 1 Jan 2100 as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top